launch crinet paltusotin prepar phase
chiasma mycapssa set disrupt acromegali market launch crinet paltusotin enter phase next
year pdufa date mycapssa approach quickli next month june crinet recent report
phase data paltusotin last month thought would good opportun provid updat acromegali
market continu believ commerci opportun mycapssa underappreci investor expect
see robust adopt patient seek altern current pain regimen inject therapi moreov
likelihood go remain concern next month think mycapssa prove popular
patient seek avoid regular visit doctor inject inde compani launch strategi plan capit
rapid growth telemedicin especi given eas patient transit mycapssa without face-to-fac
doctor visit blood work need dose titrat measur biochem respons accomplish
altern locat even home think mycapssa well posit launch world
self-administ drug market domin provid administ inject expect subsid
highlight mycapssa greater conveni need monthli doctor visit receiv treatment
enjoy time gain market accept crinet enter market paltusotin think product
long runway sinc seen product develop competitor repres meaning threat
paltusotin potenti take market leadership though mycapssa stay power paltusotin may
offer increment advantag notabl one time daili dose reduc food effect better gi toler think
allow eventu captur market leadership said expect market share remain sticki
experi patient well-control chronic therapi often hesit switch increment benefit paltusotin benefit
meaning approach leap mycapssa take transform market inject paradigm
oral therapi expect crinet pursu develop respect agent treatment
neuroendocrin tumor net leverag greater clinic experi drug crinet greater
financi resourc alreadi begun plan work net think give crinet head start
lead earlier market entri think acromegali net opportun attract neither compani
defin wholli program crinet bring acth-antagonist treatment congenit adren
hyperplasia cush diseas treatment congenit hyperinsulin chi clinic
develop end year earli expect leverag tpe technolog either alon
partner add new program pipelin report featur slide deck detail overview overal market
well detail compani program acromegali also briefli review opportun neuroendocrin
tumor net arguabl bigger commerci opportun
note price market cap reflect market close may
factset rate hcw research
definit distribut analyst rate analyst certif disclosur pleas refer page report
reiter buy price target price target base dcf valuat util
termin rate declin wacc-bas discount rate beta equiti risk premium
assum tax rate appli risk adjust valuat account probabl
success european trial posit optim data increas probabl success
although off-set higher share count follow compani recent complet equiti
offer current appli neg termin rate account potenti launch competitor howev
valuat includ potenti new applic tpe platform technolog risk includ
clinic trial risk regulatori risk competit manufactur sell treatment acromegali
effect
reiter buy crinet lower price target adjust price target
crinet base sum-of-the-part npv valuat compani on-going product target
reduc base higher share count follow compani recent equiti offer dcf model util
discount rate base compani wacc beta equiti risk premium adjust
indic probabl success paltusotin agonist acth
inhibitor discontinu anticip expect cash flow shift paltusotin
go develop net result chang npv includ termin rate
declin termin valu sinc compani use small molecul present fewer barrier
gener competit biolog assum tax rate risk includ clinic trial result might meet
expect regulatori approv risk fund risk commerci adopt effect
ligand treat
acromegali
acromegali diseas excess growth hormon
typic slow-grow benign pituitari tumor produc excess growth hormon gh
trigger oversuffici insulin-lik growth factor result excess tissu growth
long-term effect cardiomyopathi type diabet vision loss hypertens sleep apnea
diseas us popul combin us eu japan australia canada
current treatment burdensom often inadequ
surgeri radiat probabl attempt success combin
somatostatin receptor ligand srl inject patient administ monthli
srl analogu somatostatin peptid hormon inhibit gh receptor
non- incomplet respond may use daili pegvisom pasireotid recordati inject
limit srl inject therapi
radiat
lanreotid depot gaug
experienc pain inject half
experienc continu pain day later
bruis inflamm
octreotid gaug
report symptom worsen toward end
monthli dose interv
control patient still complain
feel loss independ due chronic
regularli miss work inject
oral srl may offer benefit inject acromegali
potenti incorrect
administr hcp
especi end month
need monthli hcp visit
 need take time work
 payor requir pay
particularli valuabl
patient seek
larg current market inject srl treatment
global market inject srl
global market breakdown analog type
octreotid price annual
lanreotid price annual
larg market inject srl could disrupt oral srl
mycapssa octreotid oral capsul formul
capsul leverag tpe temporarili open tight junction
small intestin improv octreotid bioavail suffici oral use
mycapssa show compar pk inject octreotid
potenti convert type inject oral
proport biochem respons
proport maintain
gh respons week
median time loss respons
median time loss respons
conduct special protocol amend
dose titrat mg capsul
withdraw criteria uln
two consecut visit highest dose
optim primari endpoint control
mycapssa
placebo arm
treatment arm achiev uln
mean treat patient end studi
nda resubmiss accept pdufa date june
launch schedul approv
placebo respond control
studi durat
optim potenti fewer breakthrough symptom
symptom vs placebo inject
therapi octreotid lanreotid
seen studi
without use rescu medic
treatment arm continu onto
optim durabl respons discontinu
mycapssa treat patient show loss respons within time
studi median loss respons time placebo arm week
treatment emerg advers effect teae seriou emerg advers effect
steae modest compar placebo studi discontinu
mycapssa well-toler durabl effect
median time loss respons
median time loss respons
teae lead studi drug
compani report octreotid lanreotid label hcw research
lanreotid
endpoint biochem control uln time-weight averag month age
adjust mycapssa respond continu mycapssa vs switch inject srl
endpoint impact treatment qualiti life gastrointestin fast requir
enrol complet respond progress random treatment phase
random phase complet particip open-label extens withdraw sub-studi
non-respond add oral dopamin agonist dostinex cabergolin
treatment
particip safeti follow-up
mg dose optim
non-respond sub-studi
follow safeti efficaci
patient remain
expect
impact time result time-
weight endpoint negat
impact miss visit
experi commerci execut
includ ceo raj kannan chief
concentr market although
patient alreadi treat
compani abl promot
effici custom
face sale rep msl
reimburs commerci
macro registri effici way identifi convert patient mycapssa
help identifi patient
provid us clinic site
provid real world data
soc burden
mycapssa offer
telemedicin mayb use convert patient mycapssa
patient could prescrib treat mycapssa via telemedicin
commit help treat physician patient telemedicin
process support servic
potenti keep patient provid offic
enhanc valu proposit pandem
potenti patient journey mycapssa convers via telemedicin
home deliveri
adjust need
maintain rang
respect investor known fundament research/du dilig
abil structur win/win deal abl fund initi stage
launch favor term
anticip catch payment
even would essenti paid royalti interest
point overal rate declin forecast
term rifa anticip would paid effect
rate sale
healthcar royalti partner gener attract return
avoid dilut doesnt becom hamstrung debt
payment cash-flow hcrp royalti total healthcar royalti royalti rate lifetim healthcar
paltusotin small molecul srl specif receptor
distinct peptide-bas mycapssa inject srl
daili oral mg reduc level phase studi
dose plasma concentr correl lower
safeti toler consist inject srl mild gastrointestin
mild elev pancreat enzym subject note observ subsequ phase
mg paltusotin lower
paltusotin potenti improv respons rate
intern desensit receptor believ contribut
lack full respons patient
paltusotin greater potenc vitro camp inhibit without receptor
intern may improv respons rate patient
hypothesi plausibl yet born clinic trial
notabl initi data edg valid human studi need
paltusotin inhibit activ vitro less receptor intern vs octreotid
endpoint baselin poorli
one-month withdraw inject srl
dose mg paltusotin
potenti up-titr mg week
 uln
 uln
evalu respons poorli control patient uln srl mo
start mg titrat valu target
titrat week
switch paltusotin
week partial respond start mg titrat valu target up-titr week depot last dose washout resum origin treatment switch exploratori endpoint baselin withdraw secondari agent cabergolin healthcar
srl-onli arm show mean chang uln vs baselin week
patient actual saw reduct baselin
potenti better control higher dose vs inject
use rescu treatment particip entir studi
increas level week suggest lack suppress effect
remnant prior depot inject medic consist earlier human studi
paltusotin well-toler
teae mild consist phase studi
safeti signal date regard vital sign ecg
prophylact treatment use potenti gastrointestin effect
elev pancreat enzym observ allevi concern
phase studi patient show mild elev
entir studi date
elev
proport subject who
uln averag week
level week
growth hormon level week
patient assess symptom
conduct biochem control patient
one-month withdraw inject srl
dose mg paltusotin
potenti up-titr mg week
random withdraw uln
washout resumpt normal
evalu respons biochem control patient uln srl therapi
start mg titrat valu
target titrat week
switch paltusotin
week ssa respond washout resum origin treatment endpoint respond vs placebo start mg titrat valu target up-titr week depot last dose placebo activ switch random withdraw healthcar
paltusotin may offer advantag mycapssa acromegali
tpe capsul
must taken empti stomach
expect reduc
still need born late-stag studi
crinet still need final test new formul
even potenti
advantag paltusotin
expect mycapssa market
share go sticki
edg expect basi paltusotin regulatori strategi
evolv test paltusotin less sever biochem control acromegali patient
evolv stop enrol current enrol patient complet studi
top-line data edg evol expect
combin data present end phase meet
phase initi expect
paltusotin regulatori strategi pool edg evolv data
end phase
current particip complet studi
potenti phase design paltusotin
like optim expect
focu biochem control patient
crinet may includ non-biochem control patient open label extens
potenti includ higher dose use edg evolv
anticip longer larger optim
expect use novel as-to-b market formul potenti food effect
paltusotin phase like mani featur optim trial
may includ patient
extens phase
placebo inject srl control arm
srl market model acromegali
us acromegali total number patient opt somatostatin analog ssa total acromegali somatostatin analog ssa therapi market share address market size number total patient treat mycapssa annual price gross sale total patient treat annual price gross sale market share breakdown oral ssa therapi market size number overal ssa therapi market size number acromegali total number patient opt somatostatin analog ssa total acromegali somatostatin analog ssa therapi market share address market size number patients- total patient treat mycapssa annual price gross sale total patient treat annual price gross sale market share breakdown oral ssa therapi market size number patient overal ssa therapi market size number healthcar
on-go product develop acromegali
acromegali activ area research although dont see program
threaten either crinet
rout admin
net enteroendocrin malign gastrointestin tract lung
non-funct net often progress unnot year diagnosi
mani diagnos advanc metastat diseas
earlier diagnosi increas biomark imag technolog improv
us case orphan diseas though common gastrointestin tumor type
patient carcinoid syndrom highli symptomat subset net popul
present net
us popul
function tumor secret amin serotonin
lead sever heart/liv issu
bothersom symptom typic lead diagnosi
net may previous gone unnot
therapi choic base tumor locat stage symptom patient health
slow grow asymptomat tumor surveil metastasi symptom
surgeri common first line intervent often combin follow
antiprolif symptomat control strategi use
asymptomat
symptomat
elig
resect midgut net
radiotherapi efficaci depend stage
srl therapi express net
support palli care
srl provid symptom control benefit carcinoid syndrom
srl wide use carcinoid syndrom help control symptom
sym-net patient studi satisfi diarrhea control satisfi flush
control satisfi qualiti life improv due treatment
inject srl present similar burden acromegali broader net
oral srl may offer similar benefit inject
numer studi demonstr srl provid symptom relief carcinoid syndrom
releas autogel
net depend tumor locat overexpress receptor
srl use roughli non-respect net post-
clarinet studi show signific improv progress free
surviv upon inject srl lanreotid treatment across varieti net
inject srl present similar burden acromegali
oral srl may offer similar benefit inject
median reach
develop oral srl net carcinoid syndrom
net activ pursu mycapssa though might chang post-pdufa date
origin intend pursu net immedi approv acromegali
although resourc constraint follow forc compani set
data prior clinic work acromegali help speed dose safeti dose
includ net model valuat could add
paltusotin develop carcinoid syndrom broader net indic possibl
cash equival crinet appear better posit pursu net
carcinoid syndrom appear like initi target base easier develop pathway
crn discontinu phase show improv paltusotin
paltusotin may similar advantag mycapssa net
abil avoid receptor desensitization/intern may offer benefit octreotid
net
potenti develop timelin net carcinoid syndrom
potenti carcinoid syndrom trial would like begin mid-to-l due resourc
devot mycapssa launch
crinet anticip begin carcinoid syndrom move broader net indic
envis surviv studi begin though could begin earlier
carcinoid trial assum three-month endpoint phase six-month endpoint phase
least two year endpoint deem necessari surviv studi net
potenti opportun tpe
crinet asset near clinic
potenti convert inject therapi
oral
gattex teduglutid short bowel
protein hemophilia
dyslipidemia due leptin
fertil hormon use part
vitro fertil human
lutein hormon follicl
potenti use cush diseas
congenit adren hyperplasia
could use altern
surgeri adjuv treatment
part block replac strategi
potenti use treatment
possibl altern near-tot
pancreatomi srl
effect
ind enabl activ
progress phase studi plan
late earli
note price market cap reflect market close may
factset rate hcw research
ligand treat
acromegali
acromegali diseas excess growth hormon
typic slow-grow benign pituitari tumor produc excess growth hormon gh
trigger oversuffici insulin-lik growth factor result excess tissu growth
long-term effect cardiomyopathi type diabet vision loss hypertens sleep apnea
diseas us popul combin us eu japan australia canada
current treatment burdensom often inadequ
surgeri radiat probabl attempt success combin
somatostatin receptor ligand srl inject patient administ monthli
srl analogu somatostatin peptid hormon inhibit gh receptor
non- incomplet respond may use daili pegvisom pasireotid recordati inject
limit srl inject therapi
radiat
lanreotid depot gaug
experienc pain inject half
experienc continu pain day later
bruis inflamm
octreotid gaug
report symptom worsen toward end
monthli dose interv
control patient still complain
feel loss independ due chronic
regularli miss work inject
oral srl may offer benefit inject acromegali
potenti incorrect
administr hcp
especi end month
need monthli hcp visit
 need take time work
 payor requir pay
particularli valuabl
patient seek
larg current market inject srl treatment
global market inject srl
global market breakdown analog type
octreotid price annual
lanreotid price annual
larg market inject srl could disrupt oral srl
mycapssa octreotid oral capsul formul
capsul leverag tpe temporarili open tight junction
small intestin improv octreotid bioavail suffici oral use
mycapssa show compar pk inject octreotid
potenti convert type inject oral
proport biochem respons
proport maintain
gh respons week
median time loss respons
median time loss respons
conduct special protocol amend
dose titrat mg capsul
withdraw criteria uln
two consecut visit highest dose
optim primari endpoint control
mycapssa
placebo arm
treatment arm achiev uln
mean treat patient end studi
nda resubmiss accept pdufa date june
launch schedul approv
placebo respond control
studi durat
optim potenti fewer breakthrough symptom
symptom vs placebo inject
therapi octreotid lanreotid
seen studi
without use rescu medic
treatment arm continu onto
optim durabl respons discontinu
mycapssa treat patient show loss respons within time
studi median loss respons time placebo arm week
treatment emerg advers effect teae seriou emerg advers effect
steae modest compar placebo studi discontinu
mycapssa well-toler durabl effect
median time loss respons
median time loss respons
teae lead studi drug
compani report octreotid lanreotid label hcw research
lanreotid
endpoint biochem control uln time-weight averag month age
adjust mycapssa respond continu mycapssa vs switch inject srl
endpoint impact treatment qualiti life gastrointestin fast requir
enrol complet respond progress random treatment phase
random phase complet particip open-label extens withdraw sub-studi
non-respond add oral dopamin agonist dostinex cabergolin
treatment
particip safeti follow-up
mg dose optim
non-respond sub-studi
follow safeti efficaci
patient remain
expect
impact time result time-
weight endpoint negat
impact miss visit
experi commerci execut
includ ceo raj kannan chief
concentr market although
patient alreadi treat
compani abl promot
effici custom
face sale rep msl
reimburs commerci
macro registri effici way identifi convert patient mycapssa
help identifi patient
provid us clinic site
provid real world data
soc burden
mycapssa offer
telemedicin mayb use convert patient mycapssa
patient could prescrib treat mycapssa via telemedicin
commit help treat physician patient telemedicin
process support servic
potenti keep patient provid offic
enhanc valu proposit pandem
potenti patient journey mycapssa convers via telemedicin
home deliveri
adjust need
maintain rang
respect investor known fundament research/du dilig
abil structur win/win deal abl fund initi stage
launch favor term
anticip catch payment
even would essenti paid royalti interest
point overal rate declin forecast
term rifa anticip would paid effect
rate sale
healthcar royalti partner gener attract return
avoid dilut doesnt becom hamstrung debt
payment cash-flow hcrp royalti total healthcar royalti royalti rate lifetim healthcar
paltusotin small molecul srl specif receptor
distinct peptide-bas mycapssa inject srl
daili oral mg reduc level phase studi
dose plasma concentr correl lower
safeti toler consist inject srl mild gastrointestin
mild elev pancreat enzym subject note observ subsequ phase
mg paltusotin lower
paltusotin potenti improv respons rate
intern desensit receptor believ contribut
lack full respons patient
paltusotin greater potenc vitro camp inhibit without receptor
intern may improv respons rate patient
hypothesi plausibl yet born clinic trial
notabl initi data edg valid human studi need
paltusotin inhibit activ vitro less receptor intern vs octreotid
endpoint baselin poorli
one-month withdraw inject srl
dose mg paltusotin
potenti up-titr mg week
 uln
 uln
evalu respons poorli control patient uln srl mo
start mg titrat valu target
titrat week
switch paltusotin
week partial respond start mg titrat valu target up-titr week depot last dose washout resum origin treatment switch exploratori endpoint baselin withdraw secondari agent cabergolin healthcar
srl-onli arm show mean chang uln vs baselin week
patient actual saw reduct baselin
potenti better control higher dose vs inject
use rescu treatment particip entir studi
increas level week suggest lack suppress effect
remnant prior depot inject medic consist earlier human studi
paltusotin well-toler
teae mild consist phase studi
safeti signal date regard vital sign ecg
prophylact treatment use potenti gastrointestin effect
elev pancreat enzym observ allevi concern
phase studi patient show mild elev
entir studi date
elev
proport subject who
uln averag week
level week
growth hormon level week
patient assess symptom
conduct biochem control patient
one-month withdraw inject srl
dose mg paltusotin
potenti up-titr mg week
random withdraw uln
washout resumpt normal
evalu respons biochem control patient uln srl therapi
start mg titrat valu
target titrat week
switch paltusotin
week ssa respond washout resum origin treatment endpoint respond vs placebo start mg titrat valu target up-titr week depot last dose placebo activ switch random withdraw healthcar
paltusotin may offer advantag mycapssa acromegali
tpe capsul
must taken empti stomach
expect reduc
still need born late-stag studi
crinet still need final test new formul
even potenti
advantag paltusotin
expect mycapssa market
share go sticki
edg expect basi paltusotin regulatori strategi
evolv test paltusotin less sever biochem control acromegali patient
evolv stop enrol current enrol patient complet studi
top-line data edg evol expect
combin data present end phase meet
phase initi expect
paltusotin regulatori strategi pool edg evolv data
end phase
current particip complet studi
potenti phase design paltusotin
like optim expect
focu biochem control patient
crinet may includ non-biochem control patient open label extens
potenti includ higher dose use edg evolv
anticip longer larger optim
expect use novel as-to-b market formul potenti food effect
paltusotin phase like mani featur optim trial
may includ patient
extens phase
placebo inject srl control arm
srl market model acromegali
us acromegali total number patient opt somatostatin analog ssa total acromegali somatostatin analog ssa therapi market share address market size number total patient treat mycapssa annual price gross sale total patient treat annual price gross sale market share breakdown oral ssa therapi market size number overal ssa therapi market size number acromegali total number patient opt somatostatin analog ssa total acromegali somatostatin analog ssa therapi market share address market size number patients- total patient treat mycapssa annual price gross sale total patient treat annual price gross sale market share breakdown oral ssa therapi market size number patient overal ssa therapi market size number healthcar
on-go product develop acromegali
acromegali activ area research although dont see program
threaten either crinet
rout admin
net enteroendocrin malign gastrointestin tract lung
non-funct net often progress unnot year diagnosi
mani diagnos advanc metastat diseas
earlier diagnosi increas biomark imag technolog improv
us case orphan diseas though common gastrointestin tumor type
patient carcinoid syndrom highli symptomat subset net popul
present net
us popul
function tumor secret amin serotonin
lead sever heart/liv issu
bothersom symptom typic lead diagnosi
net may previous gone unnot
therapi choic base tumor locat stage symptom patient health
slow grow asymptomat tumor surveil metastasi symptom
surgeri common first line intervent often combin follow
antiprolif symptomat control strategi use
asymptomat
symptomat
elig
resect midgut net
radiotherapi efficaci depend stage
srl therapi express net
support palli care
srl provid symptom control benefit carcinoid syndrom
srl wide use carcinoid syndrom help control symptom
sym-net patient studi satisfi diarrhea control satisfi flush
control satisfi qualiti life improv due treatment
inject srl present similar burden acromegali broader net
oral srl may offer similar benefit inject
numer studi demonstr srl provid symptom relief carcinoid syndrom
releas autogel
net depend tumor locat overexpress receptor
srl use roughli non-respect net post-
clarinet studi show signific improv progress free
surviv upon inject srl lanreotid treatment across varieti net
inject srl present similar burden acromegali
oral srl may offer similar benefit inject
median reach
develop oral srl net carcinoid syndrom
net activ pursu mycapssa though might chang post-pdufa date
origin intend pursu net immedi approv acromegali
although resourc constraint follow forc compani set
data prior clinic work acromegali help speed dose safeti dose
includ net model valuat could add
paltusotin develop carcinoid syndrom broader net indic possibl
cash equival crinet appear better posit pursu net
carcinoid syndrom appear like initi target base easier develop pathway
crn discontinu phase show improv paltusotin
paltusotin may similar advantag mycapssa net
abil avoid receptor desensitization/intern may offer benefit octreotid
net
potenti develop timelin net carcinoid syndrom
potenti carcinoid syndrom trial would like begin mid-to-l due resourc
devot mycapssa launch
crinet anticip begin carcinoid syndrom move broader net indic
envis surviv studi begin though could begin earlier
carcinoid trial assum three-month endpoint phase six-month endpoint phase
least two year endpoint deem necessari surviv studi net
potenti opportun tpe
crinet asset near clinic
potenti convert inject therapi
oral
gattex teduglutid short bowel
protein hemophilia
dyslipidemia due leptin
fertil hormon use part
vitro fertil human
lutein hormon follicl
potenti use cush diseas
congenit adren hyperplasia
could use altern
surgeri adjuv treatment
part block replac strategi
potenti use treatment
possibl altern near-tot
pancreatomi srl
effect
ind enabl activ
progress phase studi plan
late earli
note price market cap reflect market close may
factset rate hcw research
revenu licens agreement
research develop
sell gener administr
incom loss incom tax provis
accret redeem convert prefer stock
net loss attribut common stockhold
revenu licens agreement
research develop
sell gener administr
incom loss incom tax provis
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc chma-u
rate price target histori crinet inc crnx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
dougla tsao certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli relat
specif recommend view express research report neither member household
offic director advisori board member compani
none research analyst research analyst household financi interest secur inc
inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc non-invest
bank servic previou month
firm affili receiv compens inc inc invest
bank servic within twelv month seek compens compani mention report
invest bank servic within three month follow public research report
 wainwright co llc manag co-manag public offer secur inc crinet
pharmaceut inc past month
firm make market inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
